Immunology Brands

Prescription immunosuppressant medication (mycophenolate mofetil) for preventing organ rejection in transplant recipients, originally developed by Syntex Laboratories and now marketed by Roche.

Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.

Prescription immunosuppressant medication for treating relapsing-remitting multiple sclerosis, manufactured and marketed by Novartis.

Pfizer's oral JAK inhibitor (tofacitinib), FDA approved November 6, 2012, as the first JAK inhibitor approved in the United States, indicated for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, juvenile idiopathic arthritis, and ankylosing spondylitis, subject to a strengthened black box warning in September 2021 following the ORAL Surveillance trial showing increased risks of serious cardiovascular events, cancer, blood clots, and death compared to TNF inhibitors.